Start INTENSIVE lipid lowering early after an ACS - the lower the LDL the better the plaque stabilisation -adding #PCSK9 early - HUYGENS trial #ESCCongress European Society of Cardiology

#PCSK9 inhibition compared with placebo reduced ⤵️ the primary endpoint of death or need for intubation and IL-6 levels in severe #COVID-19 jacc.org/doi/epdf/10.10… via JACC Journals NYU CVD Prevention PCSK9 Forum American College of Cardiology

Surprised? Raul Santos Michael J. Blaha Roger Blumenthal Ron Blankstein Michael D. Shapiro Dr. Martha Gulati ♥️🫀❤️‍🩹🇨🇦 #EASCongress2023 jamanetwork.com/journals/jama/…

GDMT for HF Immediate vs delayed Quadruple vs double or triple Comprehensive vs incomplete Target dosing vs suboptimal The difference between Optimal clinical outcomes vs events that could have been prevented but were unfortunately not

Data speaks for itself for the "umpteenth time" lower is better - Give it up deniers

⚠️Effects of icosapent ethyl on residual CV risk according to predicted baseline risk: #REDUCE-IT 👉Among patients with ASCVD and ↗️TG levels, icosapent ethyl significantly ⤵️ MACE across all quartiles of baseline CVD risk 👉5-year ARRs are largest for 👥 with the highest

Muvalaplin, a selective small molecule inhibitor of Lp(a) formation, was not associated with tolerability concerns and lowered Lp(a) levels up to 65% following daily administration for 14 days. ja.ma/3OSycvP #ESCCongress

• #PCSK9i monotherapy is associated w/ a ⬇️ incidence of a composite of MI, stroke & 💀 • The expression of inflamm proteins within the plaque is associated w/ the incidence of #MI, stroke, & 💀 🔗 atherosclerosis-journal.com/article/S0021-… Celestino Sardu Pasquale Paolisso Arturo Cesaro European Atherosclerosis Society

An excellent review of the power of zero and the low prevalence of non-calcified plaque when CAC = 0. authors.elsevier.com/c/1hudq6tu1i7c… by my former fellows - Irfan Zeb and Yasmin Hamirani

Lp(a) | Prof Florian Kronenberg ❤️ Lp(a) is an independent risk factor for CVD & should be measured at least once in a 👥 lifetime If Lp(a) is ⬆️ we should 👇🏼 🔹Test the family, much like what we do in FH 🔹⬇️ modifiable CVD risk factors (ie LDL) as early as possible

Thank you, Dr. Erin D. Michos, M.D.. Our📜reveals increased risks in🤰with RA, including preeclampsia, PPCM, arrhythmias, AKI, and VTE during delivery admissions. A collaborative approach involving rheumatologists, cardiologists, and high-risk ob is needed OHSU Cardiology Fellowship #CardioTwitter

#Obesity, #dyslipidemia, & #CardiovascularDisease A joint expert review from the Obesity Medicine Association & National Lipid Association sciencedirect.com/science/articl…

👉High Lp(a): Actionable strategies for risk assessment and mitigation ☝️This review focuses on the identification and clinical management of patients with high Lp(a). Specifically, the authors highlight the clinical value of measuring Lp(a) and its use in determining Lp(a)

MUST READ - New Term SMurfs - (1) IT IS CRIMINAL FOR CLINICIANS NOT TO TEST LP(a) IN ALL. We really need to take Lp(a) increases very seriously. - Way outside of the box, but I am at the point to advise Lp(a) patients to take a PCSK9i to blow away apoB and at least lower Lp(a)

How about this study (in press) - EZETIMIBE as a player to prevent Alzheimer's Disease and Related Dementia (ARRD). See Aging Biology | Ezetimibe lowers risk of Alzheimer’s and Related Dementias over 7-fold, reducing aggregation in model systems by inhibiting 14-3-3G::hexokinase

A common misconception is the thought that low LDL-C might increase risk of hemorrhagic stroke or dementia. This great review provides a summary as to why these claims are unfounded. acc.org/latest-in-card….

New Study Provides Comprehensive Insights into Rare #Triglyceride Disorder. Christie Ballantyne Journal of Clinical Lipidology BCM Department of Medicine The Texas Heart Institute bcm.edu/news/new-study…

📢NEW NLA & American Geriatrics Society expert clinical consensus on managing #hypercholesterolemia in adults older than 75 years without a history of #ASCVD. Read the article now: sciencedirect.com/science/articl…

Treatment of heterozygous familial hypercholesterolaemia in children: is lower better? academic.oup.com/eurjpc/article…